Quince Therapeutics (QNCX) – Investment Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Quince Therapeutics (NASDAQ: QNCX) in the last few weeks:

• 8/22/2026 – Quince Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/20/2026 – Quince Therapeutics is now covered by Craig Hallum. They set a “buy” rating and a $68.00 price target on the stock.
• 8/18/2026 – Quince Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $70.00 price target on the stock.
• 8/12/2026 – Quince Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 7/29/2026 – Quince Therapeutics had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 7/29/2026 – Quince Therapeutics is now covered by Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $82.00 price target on the stock.
• 6/29/2026 – Quince Therapeutics was upgraded by Lifesci Capital to “strong-buy”.

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.